Shares of Cipla declined over 3% in trade today after reports flagged a potential regulatory and earnings risk linked to its key US product, Lanreotide. As of 9:48 AM, the shares were trading 2.62% higher at Rs 1,490.70.
The pressure on the stock follows very serious Form 483 observations issued by the US Food and Drug Administration (US FDA) to Pharmathen, a Greece-based contract manufacturing organisation (CMO). The observations relate to Pharmathen’s Rodopi manufacturing facility, which is Cipla’s sole manufacturing partner for Lanreotide.
According to brokerages, the nine Form 483 observations highlight multiple concerns at the Rodopi unit. These include risks of microbiological contamination involving Gram-negative bacteria, deficiencies in aseptic manufacturing practices, higher particulate reject limits, rejected production batches, and inadequate investigations into out-of-specification (OOS) results. Collectively, these issues raise red flags around both manufacturing quality and data integrity.
This development is particularly significant for Cipla because Lanreotide is its largest product in the US market. Any major disruption at Pharmathen’s Rodopi facility could directly affect the supply of Lanreotide, unless Cipla has an alternative manufacturing arrangement in place. Market participants are factoring in the possibility of regulatory follow-ups, remediation timelines, or production slowdowns, all of which could weigh on near-term earnings visibility.
Brokerage noted that around ~10% of Cipla’s EBITDA is at risk if Lanreotide manufacturing faces prolonged disruption. Given the importance of the US business to Cipla’s overall profitability, the compliance overhang has been viewed as materially negative by investors, triggering the sell-off in today’s session.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.